Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prothrombinex-VF is an Australian-produced, plasma-derived three-factor prothrombin complex concentrate (3F-PCC) manufactured by CSL Behring. It is derived from human plasma collected by Australian Red Cross Lifeblood and contains concentrated human coagulation factors II, IX, and X, along with low levels of antithrombin III and heparin sodium to reduce thrombotic risk. Prothrombinex-VF is indicated for the treatment and perioperative prophylaxis of bleeding in patients with acquired deficiency of prothrombin complex factors (such as those induced by vitamin K antagonists like warfarin) or congenital deficiencies of factors II, IX, or X when purified single-factor products are unavailable. It is administered intravenously as a reconstituted powder.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human prothrombin complex (CSL Limited).